Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas

SIMPLE SUMMARY: Chondrosarcoma is a rare bone tumor characterized by the secretion of a cartilage-like extracellular matrix. Its treatment poses major challenges, since chondrosarcoma is resistant to chemotherapy and radiotherapy. Consequently, chondrosarcoma treatment has been limited over the past...

Descripción completa

Detalles Bibliográficos
Autores principales: Lhuissier, Eva, Aury-Landas, Juliette, Lenté, Marion, Boumediene, Karim, Baugé, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472299/
https://www.ncbi.nlm.nih.gov/pubmed/34572877
http://dx.doi.org/10.3390/cancers13184648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472299/
https://www.ncbi.nlm.nih.gov/pubmed/34572877
http://dx.doi.org/10.3390/cancers13184648

Ejemplares similares